The Evaluation of the Oncologic Patient for Drug-Induced Pneumonitis
Seminars in Respiratory and Critical Care Medicine · 01.08.2026 · 47 (04) · 446-456
DOI: 10.1055/a-2703-4574 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, erschienen am 01.08.2026. Verfasst von Terra C Swanson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, Unit…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Lung Diseases, Interstitial, Pneumonia. Die Arbeit nennt 106 Literaturangaben.
Abstract (Originalsprache)
The National Cancer Institute (NCI) estimates that over 2 million Americans will be diagnosed with cancer in 2025. A significant proportion of these patients will receive chemotherapeutics, radiation, molecularly targeted therapies, or immunotherapies—many of which are associated with pulmonary toxicity. Drug-induced interstitial lung disease (D-ILD) is a growing and well-recognized complication of cancer-related therapies, carrying substantial morbidity and mortality. In addition to its direct health impact, D-ILD often necessitates modification or discontinuation of cancer treatment, further complicating oncologic care. As such, pulmonologists must be proficient in the evaluation and management of suspected D-ILD. In this review, we propose a structured approach to assessing patients with malignancy who present with diffuse parenchymal lung disease. We also summarize commonly implicated cancer therapies and their associated pulmonary toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States.
- Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States.
Zitieren
APA
Swanson, T. C., Kinder, B. W., & Clark, J. M. (2026). The Evaluation of the Oncologic Patient for Drug-Induced Pneumonitis. Seminars in Respiratory and Critical Care Medicine, 47(04), 446-456. https://doi.org/10.1055/a-2703-4574
Vancouver
Swanson TC, Kinder BW, Clark JM. The Evaluation of the Oncologic Patient for Drug-Induced Pneumonitis. Seminars in Respiratory and Critical Care Medicine. 2026;47(04):446-456. doi:10.1055/a-2703-4574
BibTeX
@article{Swanson2026,
author = {Swanson, Terra C and Kinder, Brent W and Clark, Joshua M},
title = {The Evaluation of the Oncologic Patient for Drug-Induced Pneumonitis},
journal = {Seminars in Respiratory and Critical Care Medicine},
year = {2026},
volume = {47},
number = {04},
pages = {446--456},
doi = {10.1055/a-2703-4574}
}
EUVIMED